A role for ATP in tubular fibrosis in the diabetic kidney by Hills, Claire et al.
Abstract – Diabetes UK, 2017 
 
A role for ATP in tubular fibrosis in the diabetic kidney 
 
Hills CE, Price GW1, Squires PE1,  
1. Joseph Banks Laboratories, University of Lincoln, Lincoln, LN6 6DL 
 
 
 
Aims: Recent studies link elevated hemi-channel mediated ATP release to increased tissue fibrosis in 
disease. This study examines a role for ATP in extracellular matrix (ECM) remodelling and increased 
secretion of fibrotic mediators in kidney tubular epithelial cells.  
 
Methods: Human kidney (HK2) tubular epithelial cells were treated with ATPgS (1-100µM) for 48hrs. 
Cell morphology and cytoskeletal reorganisation were assessed by phase contrast microscopy and 
immunocytochemistry respectively. Cell viability was determined by MTT and crystal violet assays. 
Collagen I, IV, Fibronectin and Laminin expression were determined by immunoblot analysis, whilst 
Interleukin-6 and Beta-Nerve Growth Factor (b-NGF) secretion were assessed by cytokine arrays. 
 
Results: ATPgs (1-100µM) failed to evoke any significant change in HK2 morphology, cytoskeletal 
reorganisation or cell viability at 48hrs. Immunoblotting confirmed that ATPgs up-regulated Collagen I 
to 177±12%, 182±21%, and 187±21% (n=3 P<0.01) and Collagen IV to 233±26%, 344±18.5%, and 
390±10% compared to control  (n=3 P<0.001) at 1, 10 and 100 µM. In addition, ATPgs significantly 
increased expression of Fibronectin to 274±47%, 350±23%, and 433±81% of control  (n=3 P<0.01) at 
1, 10 and 100 µM, yet failed to alter expression of ECM protein Laminin. Array analysis of supernatant 
from ATPgs treated cells confirmed a significant increase in secretion of both IL-6 and b-NGF to 
261±24 and 194±44 respectively compared to control (n=3 P<0.01). 
 
Conclusions: The current study suggests that glucose-evoked increases in hemi-channel mediated 
ATP release may contribute to the underlying pathology of tubulointerstitial fibrosis in the diabetic 
kidney.  
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